379 related articles for article (PubMed ID: 10077623)
1. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Overwijk WW; Lee DS; Surman DR; Irvine KR; Touloukian CE; Chan CC; Carroll MW; Moss B; Rosenberg SA; Restifo NP
Proc Natl Acad Sci U S A; 1999 Mar; 96(6):2982-7. PubMed ID: 10077623
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
[TBL] [Abstract][Full Text] [Related]
3. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
Bronte V; Apolloni E; Ronca R; Zamboni P; Overwijk WW; Surman DR; Restifo NP; Zanovello P
Cancer Res; 2000 Jan; 60(2):253-8. PubMed ID: 10667570
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
5. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
Hara I; Takechi Y; Houghton AN
J Exp Med; 1995 Nov; 182(5):1609-14. PubMed ID: 7595233
[TBL] [Abstract][Full Text] [Related]
6. Autoimmune etiology of generalized vitiligo.
Le Poole IC; Luiten RM
Curr Dir Autoimmun; 2008; 10():227-43. PubMed ID: 18460889
[TBL] [Abstract][Full Text] [Related]
7. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
[TBL] [Abstract][Full Text] [Related]
8. GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1.
Rausch MP; Irvine KR; Antony PA; Restifo NP; Cresswell P; Hastings KT
J Immunol; 2010 Sep; 185(5):2828-35. PubMed ID: 20668223
[TBL] [Abstract][Full Text] [Related]
9. Tumor immunity and autoimmunity induced by immunization with homologous DNA.
Weber LW; Bowne WB; Wolchok JD; Srinivasan R; Qin J; Moroi Y; Clynes R; Song P; Lewis JJ; Houghton AN
J Clin Invest; 1998 Sep; 102(6):1258-64. PubMed ID: 9739060
[TBL] [Abstract][Full Text] [Related]
10. Peripheral CD8+ T cell tolerance against melanocytic self-antigens in the skin is regulated in two steps by CD4+ T cells and local inflammation: implications for the pathophysiology of vitiligo.
Steitz J; Brück J; Lenz J; Büchs S; Tüting T
J Invest Dermatol; 2005 Jan; 124(1):144-50. PubMed ID: 15654968
[TBL] [Abstract][Full Text] [Related]
11. An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen.
Rausch MP; Hastings KT
PLoS One; 2015; 10(4):e0123332. PubMed ID: 25875653
[TBL] [Abstract][Full Text] [Related]
12. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
Overwijk WW; Tsung A; Irvine KR; Parkhurst MR; Goletz TJ; Tsung K; Carroll MW; Liu C; Moss B; Rosenberg SA; Restifo NP
J Exp Med; 1998 Jul; 188(2):277-86. PubMed ID: 9670040
[TBL] [Abstract][Full Text] [Related]
13. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
14. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
Overwijk WW; Restifo NP
Crit Rev Immunol; 2000; 20(6):433-50. PubMed ID: 11396680
[TBL] [Abstract][Full Text] [Related]
15. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
[TBL] [Abstract][Full Text] [Related]
16. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
Ji Q; Gondek D; Hurwitz AA
J Immunol; 2005 Aug; 175(3):1456-63. PubMed ID: 16034082
[TBL] [Abstract][Full Text] [Related]
17. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
18. The immune response to melanoma is limited by thymic selection of self-antigens.
Träger U; Sierro S; Djordjevic G; Bouzo B; Khandwala S; Meloni A; Mortensen M; Simon AK
PLoS One; 2012; 7(4):e35005. PubMed ID: 22506061
[TBL] [Abstract][Full Text] [Related]
19. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity.
Hawkins WG; Gold JS; Dyall R; Wolchok JD; Hoos A; Bowne WB; Srinivasan R; Houghton AN; Lewis JJ
Surgery; 2000 Aug; 128(2):273-80. PubMed ID: 10923004
[TBL] [Abstract][Full Text] [Related]
20. Type I interferon signaling limits viral vector priming of CD8
Riding RL; Richmond JM; Fukuda K; Harris JE
Pigment Cell Melanoma Res; 2021 Jul; 34(4):683-695. PubMed ID: 33040466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]